CRISM Therapeutics Corporation

CRTX

VGG042401262

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:19 2024-07-05 EDT			5-day change	1st Jan Change
15.75 ^GBX	-4.55%		+200.00%	+9.38%

07-04	Crism Therapeutics Affirms Plan to File Clinical Trial Application for Lead Product in H2	MT
07-03	Crism flags contract talks, reacts to share price surge	AN

Crism flags contract talks, reacts to share price surge

July 03, 2024 at 02:04 pm

Crism Therapeutics Corp - Pharmaceutical company headquartered in Surrey - Notes the increase in the share price on Wednesday, confirms that it is not aware of any specific reason for the increase. Points out the share price has fallen since admission to AIM in May. Continues to work on its stated strategy of submitting a clinical trial application in the second half of 2024 for its lead product, ChemoSeed. Also at contract stage to provide services with an early stage UK small and medium sized enterprise who are seeking to utilise Crism's drug formulation expertise. The value of that contract would be around GBP230,000.

Current stock price: 25.50 pence, more than quadrupled on Wednesday in London

12-month change: down 29%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about CRISM Therapeutics Corporation

Crism Therapeutics Affirms Plan to File Clinical Trial Application for Lead Product in H2	07-04	MT
Crism flags contract talks, reacts to share price surge	07-03	AN
Crism has first day of trade on AIM after name change, buy	05-31	AN
Amur Minerals confirms Extruded buy, name change and board shake-up	05-29	AN
Amur Minerals agrees reverse takeover of Extruded Pharma	05-13	AN
Amur Minerals Signs Reverse Takeover Deal With Extruded Pharmaceuticals	05-13	MT
Amur Minerals Corporation executed a share and purchase agreement to acquire Extruded Pharmaceuticals Ltd for £5.5 million.	05-12	CI
Amur Minerals swings to profit in 2023 as costs fall	05-10	AN
Amur Minerals Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	05-10	CI
EARNINGS AND TRADING: Impairment charge pushes Quartix into the red	03-04	AN
Amur Minerals Advances Reverse Takeover Deal	03-04	MT
Amur Minerals reports widened interim loss as reviews opportunities	23-09-25	AN
Amur Minerals Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-25	CI
Amur Minerals Corporation Announces Special Dividend	23-09-25	CI
Tintra receives bid approach; NCC trading in line	23-09-07	AN
FTSE 100 Closes Up 0.21% on Pound Weakness	23-09-07	DJ
UK Inflation Expectations Fall, Boosting Prospects for BOE Rate Pause	23-09-07	DJ
UK Gilt Yields Fall on Rising Expectations of a BOE Rate Pause	23-09-07	DJ
FTSE 100 Falls After Weak Performance in Asian Markets	23-09-07	DJ
Amur Minerals Shares Cease Trading on London Bourse's AIM Submarket	23-09-07	MT
Amur Minerals Notes AIM’s Reverse Takeover Requirement	23-08-15	MT
FTSE 100 Closes Down as Investors Driven into Risk-Off Mood	23-08-08	DJ
Sterling Likely to Fall in Longer Run as Markets Overestimate Rate Prospects	23-08-08	DJ
Amur Minerals ends discussions over possible Ascent Resources takeover	23-08-08	AN
FTSE 100 Edges Lower as Miners Fall After Weak China Trade Data, Glencore Earnings	23-08-08	DJ

Chart CRISM Therapeutics Corporation

Duration

Period

More charts

Company Profile

CRISM Therapeutics Corporation, formerly Amur Minerals Corporation, is a British Virgin Islands-based pharmaceutical company. The Company has developed a drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy. Its lead product, ChemoSeed, is a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and can be implanted directly into a tumor or the resection margin following the removal of a tumor, thereby ensuring that effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. It seeks to use ChemoSeed to treat high grade gliomas, a brain tumor with no satisfactory treatment. The Company also offers formulation and consultancy services. It provides assistance and services to improve the bioavailability of poorly soluble drugs. It offers remixers and extruders of various sizes.

Sector

Pharmaceuticals

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CRISM THERAPEUTICS CORPORATION	+9.38%	1.76M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B
PFIZER, INC.	-2.57%	159B